Literature DB >> 17685651

Cucurbitane-type triterpenoids from the fruits of Momordica charantia and their cancer chemopreventive effects.

Toshihiro Akihisa1, Naoki Higo, Harukuni Tokuda, Motohiko Ukiya, Hiroyuki Akazawa, Yuichi Tochigi, Yumiko Kimura, Takashi Suzuki, Hoyoku Nishino.   

Abstract

Thirteen cucurbitane-type triterpene glycosides, including eight new compounds named charantosides I (6), II (7), III (10), IV (11), V (12), VI (13), VII (16), and VIII (17), and five known compounds, 8, 9, 14, 15, and 18, were isolated from a methanol extract of the fruits of Japanese Momordica charantia. The structures of the new compounds were determined on the basis of spectroscopic methods. On evaluation of these triterpene glycosides and five other cucurbitane-type triterpenes, 1-5, also isolated from the extract of M. charantia fruits, for their inhibitory effects on the induction of Epstein-Barr virus early antigen (EBV-EA) by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells, these compounds showed inhibitory effects on EBV-EA induction with IC(50) values of 200-409 mol ratio/32 pmol TPA. In addition, upon evaluation of compounds 1-5 for inhibitory effects against activation of (+/-)-(E)-methyl-2[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitrogen oxide (NO) donor, compounds 1-3 showed moderate inhibitory effects. Compounds 1 and 2 exhibited marked inhibitory effects in both 7,12-dimethylbenz[a]anthracene (DMBA)- and peroxynitrite (ONOO-; PN)-induced mouse skin carcinogenesis tests.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17685651     DOI: 10.1021/np068075p

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  18 in total

1.  Design, synthesis and experimental validation of novel potential chemopreventive agents using random forest and support vector machine binary classifiers.

Authors:  Brienne Sprague; Qian Shi; Marlene T Kim; Liying Zhang; Alexander Sedykh; Eiichiro Ichiishi; Harukuni Tokuda; Kuo-Hsiung Lee; Hao Zhu
Journal:  J Comput Aided Mol Des       Date:  2014-05-20       Impact factor: 3.686

2.  Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: "reverse pharmacology" and "bedside to bench" approach.

Authors:  Bharat B Aggarwal; Sahdeo Prasad; Simone Reuter; Ramaswamy Kannappan; Vivek R Yadev; Byoungduck Park; Ji Hye Kim; Subash C Gupta; Kanokkarn Phromnoi; Chitra Sundaram; Seema Prasad; Madan M Chaturvedi; Bokyung Sung
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

Review 3.  Bitter melon: a panacea for inflammation and cancer.

Authors:  Prasad R Dandawate; Dharmalingam Subramaniam; Subhash B Padhye; Shrikant Anant
Journal:  Chin J Nat Med       Date:  2016-02

4.  Inhibition of nuclear transcription factor-κB and activation of peroxisome proliferator-activated receptors in HepG2 cells by cucurbitane-type triterpene glycosides from Momordica charantia.

Authors:  Nguyen Xuan Nhiem; Pham Hai Yen; Nguyen Thi Thanh Ngan; Tran Hong Quang; Phan Van Kiem; Chau Van Minh; Bui Huu Tai; Nguyen Xuan Cuong; Seok Bean Song; Young Ho Kim
Journal:  J Med Food       Date:  2012-01-16       Impact factor: 2.786

Review 5.  Bitter melon: antagonist to cancer.

Authors:  Pratibha Nerurkar; Ratna B Ray
Journal:  Pharm Res       Date:  2010-03-03       Impact factor: 4.200

6.  Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells.

Authors:  Deepanshi Dhar; Gagan Deep; Sushil Kumar; Michael F Wempe; Komal Raina; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2018-05-18       Impact factor: 4.784

Review 7.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

8.  Antileukemic Potential of Momordica charantia Seed Extracts on Human Myeloid Leukemic HL60 Cells.

Authors:  Ramani Soundararajan; Punit Prabha; Umesh Rai; Aparna Dixit
Journal:  Evid Based Complement Alternat Med       Date:  2012-05-13       Impact factor: 2.629

Review 9.  Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome.

Authors:  Md Ashraful Alam; Riaz Uddin; Nusrat Subhan; Md Mahbubur Rahman; Preeti Jain; Hasan Mahmud Reza
Journal:  J Lipids       Date:  2015-01-12

10.  Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy.

Authors:  Deep Kwatra; Dharmalingam Subramaniam; Prabhu Ramamoorthy; David Standing; Elizabeth Moran; Ravichandiran Velayutham; Ashim Mitra; Shahid Umar; Shrikant Anant
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-06       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.